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a breakthrough in understanding the molecular basis of 
self-renewal of the pluripotent founder cells of the mamma-
lian embryo, embryonic stem (ES) cells, enabled the deri-
vation of rat ES cells and their application in transgenesis. 
We will also describe the remarkable progress that has been 
made in the development of gene editing enzymes that ena-
ble the generation of transgenic rats directly through tar-
geted genetic modifications in the genomes of zygotes. The 
simplicity, efficiency and cost-effectiveness of the CRISPR/
Cas gene editing system, in particular, mean that the abil-
ity to engineer the rat genome is no longer a limiting fac-
tor. The selection of suitable targets and gene modifications 
will now become a priority: a challenge where ES culture 
and gene editing technologies can play complementary 
roles in generating accurate bespoke rat models for study-
ing biological processes and modelling human disease.
Introduction
The study of human development and disease requires the 
use of animal models. No single model system is likely to 
be able to accurately mimic all human phenotypes, or alone 
lead to the discovery of drugs with the desired efficacy in 
humans. The choice of the most appropriate model system 
is dependent on the biological question whilst taking into 
account experimental considerations and the ability to reli-
ably report directly on the human disease. Cost-effective 
animal husbandry has resulted in a rodent model being the 
preferred option for many studies. For many reasons the rat 
has been preferred over the mouse for studies of physiol-
ogy, neurobiology, pharmacology and behaviour. Despite 
both being members of the same family, and sharing many 
common features, rat and mouse are distinctly different 
species, evolutionarily separated by 15–20 million years—a 
Abstract Since its domestication over 100 years ago, the 
laboratory rat has been the preferred experimental animal 
in many areas of biomedical research (Lindsey and Baker 
The laboratory rat. Academic, New York, pp 1–52, 2006). 
Its physiology, size, genetics, reproductive cycle, cogni-
tive and behavioural characteristics have made it a par-
ticularly useful animal model for studying many human 
disorders and diseases. Indeed, through selective breeding 
programmes numerous strains have been derived that are 
now the mainstay of research on hypertension, obesity and 
neurobiology (Okamoto and Aoki Jpn Circ J 27:282–293, 
1963; Zucker and Zucker J Hered 52(6):275–278, 1961). 
Despite this wealth of genetic and phenotypic diversity, the 
ability to manipulate and interrogate the genetic basis of 
existing phenotypes in rat strains and the methodology to 
generate new rat models has lagged significantly behind the 
advances made with its close cousin, the laboratory mouse. 
However, recent technical developments in stem cell biol-
ogy and genetic engineering have again brought the rat to 
the forefront of biomedical studies and enabled research-
ers to exploit the increasingly accessible wealth of genome 
sequence information. In this review, we will describe how 
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significant degree of separation that has resulted in a num-
ber of functional and behavioural differences (Makalowski 
and Boguski 1998). Evolved differences in social and for-
aging behaviours and stress-coping strategies have meant 
that the rat is better suited to many behavioural tasks, and 
well-established behavioural tests have been developed 
and validated for the rat. Adapting some of these tests to 
the mouse has often been impossible or difficult due to dif-
ferences in behaviour (Parker et  al. 2014). The rat is less 
stressed by human handling than the mouse, which mini-
mises any influence or variability on experimental test 
results. These behavioural differences also impact on other 
aspects of experimental investigation. The lower stress lev-
els in the rat aids live animal imaging techniques by avoid-
ing the requirement for anaesthetics that can interfere with 
normal brain activity (Febo 2011; Harris et al. 2015), and 
the larger brain of the rat affords better image resolution. 
Indeed, the larger size of the rat facilitates experimental 
procedures that were difficult or impossible to perform in 
the mouse such as the introduction of a blood vessel cath-
eter (Feduccia and Duvauchelle 2010) or procedures that 
cause too much damage in the smaller brain of the mouse 
such as introduction of an intracerebral cannula (Kokare 
et  al. 2011). There are also functional differences that 
make the rat more relevant for studying human disease. 
For example, unlike the mouse, in rats and humans the 
serotonin receptor subtype 5-HT6, which is implicated in 
a variety of mood disorders, is enriched in the basal gan-
glia (Hirst et al. 2003). The pharmacological profile of the 
mouse receptor also differs from that of rat and human 
accounting for differences in ligand binding affinity. The rat 
is the major model system for the pharmaceutical industry 
because of similarities with humans in drug binding affini-
ties and toxicological profiles, and almost every new drug 
is tested in the rat at some point.
Despite the many advantages of the rat as an experimen-
tal model, the mouse was always the preferred choice in 
the field of genetics. This was initially due to its smaller 
size and shorter reproductive cycle, but this preference 
was cemented following the derivation of mouse embry-
onic stem cells (ES) in 1981 (Evans and Kaufman 1981; 
Martin 1981). ES cells have facilitated the application of 
genome engineering technologies to create precise genetic 
modifications within the mouse genome in  vitro and 
have provided a route to the generation of custom-made 
mouse models of human disease (Capecchi 2005). How-
ever, equivalent rat ES cell lines have not been available 
until relatively recently (Buehr et al. 2008; Li et al. 2008). 
Whilst, the development of mouse ES cells has led to the 
production of numerous invaluable genetically modified 
mouse lines for biomedical research, these technological 
advantages are restricted by the limits of the mouse model 
system, the ability to record reliable data and the accuracy 
with which it reflects the human disease. For example, 
mouse models of Huntington’s disease have shown either 
no symptoms or only a rapid-onset phenotype with limited 
usefulness for neurotransplantation and in  vivo imaging. 
In contrast, the transgenic rat model exhibited adult-onset 
phenotypes, which included a slowly progressive motor 
dysfunction and histopathological and metabolic alterations 
typical of Huntington’s (von Horsten et al. 2003).
The recognised value of the rat as a biomedical model 
brought about a concerted effort by a committed and 
diverse research community, to establish the necessary 
tools and resources to assist in developing and exploiting 
new genome editing technologies and enabling comparative 
genomics (Table 1). These efforts were supported by major 
commitments from European Union and NIH–NHLBI-
funded projects to develop alternative approaches to cir-
cumvent the absence of bonafide rat ES cells. Some of the 
challenges in establishing reliable methods for collecting 
and manipulating rat embryos arise from idiosyncrasies 
of rat reproduction and preimplantation development. For 
example, the induction of ovulation through injection of 
pregnant mare gonadotrophin, although effective in mice, 
is unreliable and inefficient in rats. This difficulty was 
overcome by delivering partially purified, pig pancreas 
derived-follicle stimulating hormone using osmotic min-
ipumps, which markedly increases the yield of ova (Arm-
strong and Opavsky 1988; Charreau et al. 1996). Further-
more, culture conditions had to be established to limit the 
spontaneous activation of rat oocytes (Keefer and Schuetz 
1982), and reliably support preimplantation development, 
thus maintaining the biological potential of rat embryos in 
culture (Miyoshi 2016). Indeed, pronuclear microinjection 
has been used to generate transgenic rats since the early 
1990s, mainly for gain-of-function studies (Mullins et  al. 
1990; von Horsten et  al. 2003; Popova et  al. 2005; Leon 
et al. 2010). Phenotype-driven, forward genetic approaches 
such as chemically induced N-ethyl-N-nitrosourea (ENU) 
mutagenesis (Zan et al. 2003; Smits et al. 2004) and trans-
poson-based gene-trap systems (Lu et  al. 2007; Kitada 
et al. 2009; Ivics et al. 2014; Li et al. 2016) have been very 
successful at randomly generating knock-out rats. The deri-
vation and culture of spermatogonial stem cells (Hamra 
et al. 2005; Wu et al. 2009) together with robust screening 
methods (Yanagihara and Mizuuchi 2002; Mashimo et  al. 
2008; Izsvák et  al. 2010) have improved the efficiency of 
these approaches by reducing the ethical and financial cost, 
allowing in  vitro screening, cryogenic preservation and 
generation of transgenic rats via intra-cytoplasmic sperm 
injection (ICSI) (Dozortsev et al. 1998). The detailed ben-
efits and limitations of these approaches have been thor-
oughly reviewed elsewhere (Tesson et  al. 2005; Jacob 
et al. 2010). In this review, we will discuss recent techno-
logical advances made in the field of reverse genetics and 
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site-specific gene editing, namely the derivation of rat ES 
cells and the utilisation of the CRISPR/Cas site-specific 
nuclease system. Application of these powerful genomic 
tools has now overcome the major barriers to applying 
genetic modification to the rat, and allows researchers to 
tap into the wealth of established physiological and behav-
ioural data already available for this useful laboratory 
rodent. This will permit genetic dissection of established 
natural disease rat models and accelerate the generation of 
new and better genetic and phenotypic rat models of human 
disease.
Embryonic stem cells
Embryonic stem (ES) cell lines are derived from pluripo-
tent cells within the inner cell mass of the blastocyst, and 
are defined by three cardinal properties: (1) they undergo 
unlimited self-renewal and are effectively immortal, (2) 
they are pluripotent and differentiate into all foetal cell 
types including the germ cells and (3) they can engraft into 
a host embryo and resume normal development to gener-
ate chimaeric animals. The combination of these three 
properties makes ES cells a powerful system with which to 
explore gene function in vitro and in vivo. Indeed, the suc-
cessful derivation of mouse ES cells was a major advance 
in the development of targeted genome engineering tech-
nologies in the mouse using homologous recombination 
and the generation of genetically modified mouse models 
of human disease (Evans and Kaufman 1981; Martin 1981; 
Capecchi 2005). Nevertheless, the limitations of the mouse 
as an experimental model also fueled efforts to derive 
equivalent stem cells from species better suited to particu-
lar areas of biomedical research. Unfortunately the standard 
mouse ES cell culture conditions, consisting of serum and 
the cytokine LIF (leukaemia inhibitory factor), does not 
support the derivation and expansion of bona fide germline 
competent ES cells from the blastocysts of most other spe-
cies, including the rat. Under these conditions, the stem cell 
compartment of the rat blastocyst usually differentiates to 
form extraembryonic cell types (Buehr et  al. 2003), con-
sistent with LIF supporting the growth of rat yolk sac pre-
cursors (Chuykin et  al. 2010; Debeb et  al. 2009), thereby 
undermining the establishment of undifferentiated pluri-
potent rat cell lines. The crucial breakthrough in deriving 
genuine rat ES cells, however, arose from ground-break-
ing studies in mouse ES cells that identified key signal-
ling pathways that control self-renewal and differentiation 
Table 1  List of rat resources
Resource Available resources Reference
Rat Genome Database Genetic, genomic, phenotype and disease data consisting 
of strain, gene and QTL reports, mapping data, micros-
atellite markers, sequence data and software tools
http://www.rgd.mcw.edu/
Twigger et al. (2002)
PhysGen Phenotype database of 45 FHH and SS consomic strains
http://www.pga.mcw.edu/
Wang et al. (2015b)
MCW Gene Editing Rat Resource Centre Funded to generate ~200 knock-out rat strains based on 
nominated genes involved in hypertension and renal 
disease
http://www.rgd.mcw.edu/wg/gerrc
National Bioresource Project for the Rat (NBPR) Repository of >700 rat strains and sub-strains including 
reporter, Cre and disease lines, cryopreserved embryos 
and sperm
http://www.anim.med.kyoto-u.ac.jp/nbr/repository.aspx
Mashimo et al. (2005, 2008), 
Serikawa et al. (2009)
The Rat Phenome Project hosts phenotypic data for 109 
parameters collected from >200 inbred rat strains
http://www.anim.med.kyoto-u.ac.jp/nbr/phenome.aspx
BAC library (BAC end sequencing of F344/Stm and LE/
Stm)
http://www.anim.med.kyoto-u.ac.jp/nbr/gbrowser.aspx
http://www.dna.brc.riken.jp/en/NBRPraten.html
Kyoto University rat ENU mutant archive (KURMA). 
>5000 G1 DNA and sperm samples
http://www.anim.med.kyoto-u.ac.jp/enu/home.aspx
Rat Resource and Research Centre (RRRC) Repository of >350 rat strains and sub-strains including 
reporter, Cre and disease lines, cryopreserved embryos, 
sperm and ES cells
http://www.rrrc.us/
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(Burdon et al. 1999; Chen et al. 2006; Kunath et al. 2007; 
Stavridis et al. 2007; Ying et al. 2008; Wray et al. 2011; Yi 
et al. 2011). These studies showed that whilst the ES cell 
regulatory network supports stem cell self-renewal it also 
simultaneously poises the cells ready to differentiate, lead-
ing to the suggestion that uncoupling the effects of these 
intrinsic differentiation signals was likely to be the key to 
successful ES cell derivation.
These pioneering studies highlighted two important 
signalling pathways that promote mouse ES cell differen-
tiation. The activation of MAPK (mitogen-activated protein 
kinase) through auto-inductive FGF4 (fibroblast growth 
factor 4) signalling destabilises pluripotency (Kunath 
et  al. 2007; Stavridis et  al. 2007). However, suppression 
of this pathway by blocking FGF receptor activity or by 
more direct disruption of MAPK signalling using a small 
molecule inhibitor of the MAPK activator MEK, uncou-
ples this differentiation signal and shifts the balance in 
favour of ES cell self-renewal (Burdon et  al. 1999; Chen 
et  al. 2006; Ying et  al. 2008). The other key differentia-
tion signal is the transcriptional repressor TCF3/TCF7L1, 
which suppresses expression of a number of essential ES 
cell regulators (Sokol 2011). Wnt signalling or inhibi-
tion of its downstream target glycogen synthase kinase 
3 (GSK3) induces β-catenin activity (Ding et  al. 2000; 
ten Berge et  al. 2011) which in turn destabilises TCF3/
TCF7L1 and thereby promotes ES cell self-renewal (Wray 
et  al. 2011; Yi et  al. 2011). By combining inhibitors of 
FGFR, MEK and GSK3 signalling in a serum-free medium 
(3i:FGFR + MEK + GSK3 inhibitor or 2i:MEK + GSK3 
inhibitor culture), researchers demonstrated that ES cells 
could be derived with high efficiency, not only from mouse 
strains previously regarded as non-permissive for ES cell 
derivation (Ying et al. 2008; Nichols et al. 2009), but also 
most importantly from the rat (Buehr et al. 2008; Li et al. 
2008).
Rat ES cell derivation
The first rat ES cell studies described the derivation of 
cell lines from DA, Sprague Dawley (SD) and Fisher 
F344 strains (Buehr et al. 2008; Li et al. 2008), with sub-
sequent reports extending this to include Lewis (Meek 
et  al. 2013), Brown Norway (Zhao et  al. 2010), Wistar 
and Long Evans (Kawamata and Ochiya 2010). Collec-
tively these reports suggested that the rat genetic back-
ground is not a major barrier to establishing cell lines. 
Furthermore, in contrast to that reported for mouse ES 
cell lines cultured in serum/LIF (Schwartzberg et  al. 
1989), there is no robust evidence demonstrating strain 
incompatibility between rat ES cell and the host embryo 
for chimaera generation (Buehr et  al. 2008; Hirabayashi 
et  al. 2010; Blair et  al. 2012; Hong et  al. 2012; Meek 
et al. 2013). Nevertheless, the culture conditions and the 
genetic background of rat strains may influence the long-
term stability of the phenotype and karyotype of rat ES 
cells in culture, and contribute to the variability seen in 
germ line transmission obtained using rat ES cells (Buehr 
et al. 2008; Tong et al. 2010; Blair et al. 2012).
In one of the first studies it was shown that supple-
mentation of 2i medium with LIF improved rat ES cell 
growth (Buehr et  al. 2008), a finding supported by the 
observation that overexpression of the key LIF target, 
STAT3, restricted the differentiation of rat ES cells (Li 
et  al. 2008). Careful titration of the inhibitors used in 
the 2i medium can also affect rat ES cell self-renewal. In 
particular, the dose of GSK3 inhibitor (GSK3i), which 
determines the level of stable β-catenin, plays a role in 
modulating the balance between self-renewal and dif-
ferentiation. Unlike mouse, rat ES cells are rather sensi-
tive to the level of GSK3 inhibition, largely because they 
express elevated levels of the β-catenin regulated tran-
scription factor LEF1, which triggers the activation of 
differentiation genes. As a consequence, an appropriate 
level of GSK3i is required to avoid destabilising rat ES 
cell self-renewal (Chen et al. 2013; Meek et al. 2013). In 
a more radical modification of the standard inhibitor for-
mulation, supplementation of 2i medium with inhibitors 
of Rho-associated kinase (Rock inhibitor Y-27632) and a 
transforming growth factor-β inhibitor (TGFβi: A-83-01), 
combined with 20% foetal bovine serum, was reported 
to support efficient derivation of germline competent ES 
cells from three different strains of rat (Kawamata and 
Ochiya 2010). Although it is not clear what specific bene-
fits are afforded by the addition of serum and TGFβ inhi-
bition, the Rock inhibitor is widely used to protect human 
ES cells and epiblast stem cells from apoptosis induced 
by disaggregation at passaging (Watanabe et  al. 2007; 
Ohgushi et  al. 2010)—and may prove to have a similar 
supportive function in rat ES cell cultures. It has also 
been reported that inhibition of protein kinase C (PKC) 
alone can maintain cell lines previously established in 2i, 
and for specific strains may even be sufficient to derive 
cell lines de novo (Rajendran et al. 2013). Significantly, it 
has been shown recently that PKC inhibition in combina-
tion with 2i medium allows the isolation of human blas-
tocyst derived cell lines that appear to be analogous to 
rodent ES cells (Guo et al. 2016). Whilst further culture 
optimization may be required to ensure stable and robust 
expansion of rat ES cells in culture, it is clear that the 
2i + LIF condition has been sufficient for the derivation 
of germline competent rat ES cells in many laboratories, 
and has paved the way for exploitation of genome engi-
neering technologies in this valued species.
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Gene targeting in rat ES cells
The first reports describing the genetic modification of rat 
ES cells and their use in generating transgenic rats appeared 
in 2010. Hirayabashi et  al. demonstrated that Brown Nor-
way rat ES cells could be stably transfected with a fluores-
cent Kusabira-Orange reporter gene using electroporation, 
and could engraft host embryos and be successfully passed 
through the germ line (Hirabayashi et al. 2010). Similarly, 
ES cell-derived transgenic rats, carrying an Oct4-Venus 
stem cell-specific transgene, were generated that allowed 
tracking of Oct4 expression in transgenic blastocyst out-
growths and in the embryonic testis (Kawamata and Ochiya 
2010). The first demonstration of germline transmission of 
targeted rat ES cells was reported in the same year, where 
Tong and colleagues generated a mutant rat lacking the p53 
tumour suppressor gene (Tong et al. 2010). The mutant rats 
were prone to early development of cancer, consistent with 
previously described mouse p53 mutants, but interestingly 
the spectrum of tumour types was somewhat different in 
the two species (Yan et al. 2012). The predominant tumour 
type in the mutant rats was early onset spontaneous heman-
giosarcomas, whereas in mice the most frequent tumours 
were lymphomas. Notably, an ENU-induced p53 mutant 
rat reported in another study also displayed a bias for sar-
comas, supporting the preferential development of this 
tumour type in the rat (van Boxtel et al. 2010). The p53 het-
erozygous rats also displayed a delay in tumour onset and 
a wider spectrum of tumour types, including breast cancer 
which suggested that these mutant rats might prove to be a 
useful model for the p53-associated Li-Fraumeni syndrome 
in humans.
In the wake of the p53 knock-out study, a number of 
other laboratories have reported the use of homologous 
recombination to generate new lines of ES cell-derived 
mutant rats. Yamamoto and colleagues disrupted the pro-
tease-activated receptor 2 (PAR-2) gene, a member of a 
family of G-protein-coupled receptors that regulate smooth 
muscle activity, modulate inflammatory responses, and 
are potential therapeutic targets in some human diseases 
(Cocks et al. 1999; Kawagoe et al. 2002; Kawabata 2003; 
Yamamoto et  al. 2012). Meek and co-workers inactivated 
the gene encoding hypoxanthine phosphoribosyltransferase 
(HPRT), a key regulator of the purine salvage pathway, 
generating a mutation that in humans causes the debilitat-
ing neurological disease Lesch–Nyhan Syndrome (Lesch 
and Nyhan 1964). The Hprt mutant rats showed a deficit 
in dopamine in their brains, consistent with observations in 
human Lesch–Nyhan patients and mutant mice, and may 
therefore represent a suitable animal model to investigate 
the behavioural changes associated with HPRT deficiency 
(Meek et al. 2016). In a further demonstration of the util-
ity of the rat model, Uenoyama and colleagues knocked out 
the gene encoding rat Kisspeptin, a neuropeptide involved 
in the regulation of puberty and reproduction (Irwig et al. 
2004; Matsui et al. 2004). The larger size of the rat allowed 
a detailed analysis of hormonal profiles, exposing disrup-
tion of normal pulsatile and surge patterns of gonadotro-
pin secretion in Kisspeptin deficient rats (Uenoyama et al. 
2015).
In addition to these standard gene knock-out experi-
ments, more sophisticated targeting protocols routinely 
used in mouse have also been applied to rat ES cells. This 
includes the targeted “knock-in” of transgenes as demon-
strated by replacement of the rat Kynurenine aminotrans-
ferase II gene with a human cDNA, and the insertion of a 
ubiquitous and nuclear-targeted histone 2B-tdTomato fluo-
rescent reporter transgene into the ROSA26 locus (Yama-
moto et  al. 2015; Kobayashi et  al. 2012). Consistent with 
mouse studies, the ROSA26 locus provided a “safe har-
bour” for transgene insertion and a constitutive pattern of 
transgene expression in vivo (Goto et al. 2015; Kobayashi 
et  al. 2012). Injection of the tdTomato-reporter cells into 
mouse blastocysts generated interspecies chimaeras, thus 
demonstrating the utility of the rat cells in blastocyst com-
plementation experiments and their capacity to generate 
organs in a heterologous host.
The inclusion of a drug-resistance expression cassette in 
targeting vectors is usually required to facilitate selection 
of transfected ES cell clones, but can have adverse effects 
on regulation of a host target gene. This is usually solved 
by recombinase-mediated excision of the selective cassette 
in a second round of clonal selection. Unfortunately, this 
additional step increases the chances of rat ES cell clones 
acquiring karyotypic anomalies and the loss of develop-
mental potential. However, by using a clever technical 
trick, this second round of cloning can be avoided by incor-
porating into the cassette a transgene that drives testes-spe-
cific expression of a recombinase, thus generating a self-
excising cassette that deletes itself when the ES cells pass 
through the male germ line. This useful technical modifica-
tion obviates the requirement for a second round of clonal 
selection, and should help to improve the retention of germ 
line potential in targeted rat ES cells (Lan et al. 2016).
Whilst some concerns may remain over the stability of 
rat ES cells in culture, it is clear from these recent successes 
that rat ES cell lines are useful for generating genetically 
modified rats. Available data indicate that rat ES cell deri-
vation is robust and efficient, and the reported frequency of 
homologous recombination in rat ES cells is equivalent to 
those typically seen in mouse ES cells. The contribution 
of rat ES cells to the germline of chimaeric rats does vary 
between studies, but the high efficiencies achieved in some 
cases suggest that in under the right conditions rat ES cells 
can provide a highly effective route for introducing targeted 
mutations into the rat.
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Gene editing in the rat
The development of synthetic sequence-specific nucleases, 
commonly termed gene editors, has transformed prospects 
for introducing germ line modifications in laboratory ani-
mals and in livestock. Indeed, for researchers working 
with the rat, the enzymes represent a tool that elevates 
genetic modification in the rat to parity with the meth-
ods available for the mouse. The injection of gene editor 
mRNA or protein directly into zygotes is a highly effective 
way of introducing targeted mutations into the rat germ 
line and in many instances can substitute for manipula-
tions normally performed in embryonic stem cells. The 
three types of gene editors, zinc finger nucleases (ZFN), 
TALENs and CRISPR/Cas systems have all been used to 
genetically modify the rat genome, and the type of muta-
tions they generate can be broadly organised into two main 
categories (Fig. 1) (Geurts et al. 2009; Tesson et al. 2011; 
Li et  al. 2013a, b). In the first category, the introduction 
of a double-stranded break into a target gene by an editor 
enzyme induces the non-homologous end joining (NHEJ) 
DNA repair mechanism that re-ligates the exposed ends. If 
repaired correctly, the target site can serve as a substrate for 
another round of cleavage by an editor enzyme. If however, 
the exposed ends of DNA are subject to nuclease attack and 
then re-ligated, this leads to deletions of sequences ranging 
from a few base pairs to hundreds of base pairs, some of 
which may generate a functionally null allele. Extraneous 
DNA sequences can also be inserted at the cleavage site, 
although this occurs less frequently than deletion. A major 
advantage of NHEJ mode of mutagenesis is that it is simple 
and effective, relying only on delivery of the gene editor 
and the imprecision of this DNA repair mechanism. How-
ever, a major disadvantage is that the researcher has little 
control over the type of mutation that is generated, even 
though in some instances short regions of (micro) homol-
ogy between the cleaved ends of a chromosome can bias the 
outcome. In the second category, the inclusion of a DNA 
template molecule with homology to sequences on either 
side of the cleavage site is used by a homology-dependent 
Fig. 1  Summary of site-specific nuclease gene editing tools. Site-
specific nucleases consist of a DNA-specific binding domain fused to 
a nuclease domain. In the case of ZFNs and TALENs, the nuclease 
domain is derived from the FokI restriction endonuclease. The for-
mation of FokI homodimers is required for cleavage to occur. This 
is achieved by using pairs of ZFNs and TALENs designed to oppo-
site strands and flanking the cut site. CRISPR-mediated cleavage is 
achieved using the RNA-guided DNA nuclease, Cas9. Following 
the generation of a DSB, the DNA can be repaired either by NHEJ, 
which can generate knock-out mutations resulting from the introduc-
tion of random insertions or deletions (indels), or more precisely by 
homology-directed repair using a homologous DNA template con-
taining the desired modification to be inserted
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repair (HDR) mechanism to mend the damaged chromo-
some. This process can be highly efficient, but its main 
advantage is that it allows the introduction of precise tem-
plate-directed modifications at a target site, including the 
introduction of novel DNA sequences.
CRISPR/Cas is now generally considered the preferred 
gene editing system, due to its flexibility, ease of use and 
low cost. However, genetically modified rats have been 
generated using the other platforms, and represent a useful 
resource for researchers using the rat as their chosen model 
system. In this section, we will therefore briefly mention 
how the three most popular approaches to gene editing in 
rats evolved, starting with ZFN, moving to TALENs and 
then concluding with a description of the contemporary 
CRISPR/Cas-based systems. Meganucleases, a fourth edit-
ing platform utilising engineered forms of naturally occur-
ring restriction enzymes derived from lower order animals 
and plants, have also been used to introduce targeted muta-
tions into the rat genome (Ménoret et al. 2013) but has not 
been widely adopted and will not be discussed further here.
Editing using zinc finger nucleases
ZFNs are synthetic restriction enzymes that carry an array 
of engineered sequence-specific zinc finger DNA bind-
ing units linked to the nuclease domain of the restriction 
enzyme Fok1. The adjacent binding of two properly orien-
tated and spaced ZFNs on DNA promotes dimerisation of 
the Fok1 domain which then cleaves the DNA within the 
spacer region between the ZFN binding sites (Porteus and 
Carroll 2005). Although ZFNs can be designed to cleave 
many sequences across the genome, the sequence specific-
ity of the zinc finger domains combined with the complex-
ity of the interactions between domains mean that produc-
ing a ZFN is a complicated and non-trivial task, outwith 
the routine scope of many laboratories. Nevertheless, ZFNs 
were used in the first report of gene editing in rats, which 
showed that these synthetic nucleases were highly effec-
tive in introducing NHEJ mutations in different target genes 
at frequencies ranging from 5 to 75% of live pups born 
(Geurts et  al. 2009). The high efficiencies and short time 
frames achieved in this first study propelled ZFNs to the 
forefront of rat transgenesis and the laboratories of Geurts, 
Dwinell and Jacob embarked on a large-scale programme 
to knock-out ~200 rat genes associated with hyperten-
sion and renal disease as part of an NIH-funded resource 
programme (http://rgd.mcw.edu/wg/gerrc). A number of 
reports of disease-associated mutations in specific target 
genes have arisen from this programme, including work 
in which six genes in a locus identified in a genome wide 
association study (GWAS) were mutated individually to 
assess their contribution to a renal phenotype (Flister et al. 
2013). Other laboratories also embraced the ZFN tech-
nology to generate immunodeficient (SCID) rats that are 
suitable recipients for transplantation experiments, carry-
ing mutations in the IL2-receptor gamma and Prkdc genes 
(Mashimo et al. 2010, 2012). Cui and colleagues also dem-
onstrated the feasibility using ZFNs to direct homology-
dependent repair by successfully introducing GFP report-
ers into the Mdr1a and PXR genes of Sprague Dawley and 
Long Evans rats (Cui et al. 2011).
Although constitutive disruption of a target gene’s func-
tion can be highly informative, there are many instances 
where conditional ablation of a gene product in a tissue-
specific or temporally dependent manner is required. The 
most common way to achieve this is to create an allele 
where an essential exonic region is flanked with LoxP 
recombination sites, that when induced to recombine 
through expression of CRE recombinase delete the essen-
tial region and inactivate the target gene. Brown and col-
leagues used two pairs of ZFNs and plasmid-mediated 
HDR in a two-cut strategy to insert LoxP sites in intronic 
DNA surrounding exon 4 of the gene encoding the NMDA 
receptor subunit Grin (Brown et al. 2013). By crossing rats 
carrying the floxed Grin allele with a transgenic line of 
rats expressing CRE recombinase under the control of the 
endogenous tyrosine hydroxylase (Th) promoter, selective 
deletion of Grin function was obtained in Th—expressing 
brain and adrenal gland tissue, demonstrating the utility of 
this ZFN-mediated approach to generate conditional alleles 
in the rat. In summary, although largely superseded now 
by more flexible and less costly alternatives, ZFNs have 
proved to be highly effective and relatively specific, with 
low levels of off-target effects being reported.
TALEN‑mediated gene editing
Transcription activator-like effector nucleases (TALENs) 
have a similar basic structure to ZFNs, where the Fok1 
nuclease domain is linked to an array of nucleotide-spe-
cific DNA binding domains (TAL effectors) originally 
derived from the plant bacterium Xanthomonas. In a 
similar way to ZFNs, correctly positioned pairs of TAL-
ENs promote the formation of an active Fok1 dimer and 
cleavage of the spacer DNA between the TALEN bind-
ing sites. The relatively simple design rules where one 
TALE unit recognises one nucleotide and the availabil-
ity of ready-to-clone libraries of DNA recognition units 
make TALENs a flexible and cost-effective alternative to 
ZFNs that can be constructed in any molecular biology 
laboratory (Wright et al. 2014). Since the initial reports 
demonstrating the utility of TALENs to generate NHEJ 
(Tesson et al. 2011) and knock-in (HDR) mutant rats (De 
León et al. 2014), a number of labs have used these gene 
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editors to generate new lines of genetically modified 
rats for studying cardiovascular biology (Li et al. 2015; 
Wei et al. 2015; Zhu et al. 2015), neurobiology (Fergu-
son et al. 2013; Marsan et al. 2016; Tesson et al. 2016) 
and metabolism (Chen et al. 2016; Yu et al. 2016). These 
studies and the availability of robust protocols (Tesson 
et  al. 2016) demonstrate that TALENs are an effective, 
flexible and low-cost platform for directing targeted 
mutagenesis in the rat.
CRISPR/Cas gene editing
The clustered regularly interspaced short palindromic 
repeat (CRISPR/Cas) system is an RNA-dependent adap-
tive immune system in bacteria and archaea (Horvath 
and Barrangou 2010; Wiedenheft et  al. 2012). In this 
system, short DNA sequences generated by cleavage 
of the genome of an infectious agent, such as a phage, 
are archived within an array (CRISPR) in the bacterial 
genome. Transcription and processing of the CRISPR 
array releases CRISPR-RNAs (crRNAs) that direct a 
nuclease to selectively target and destroy the phage DNA 
in any future infection. The most commonly used sys-
tem for gene editing is derived from Streptococcus pyo-
genes, which comprises of a trans-acting crRNA (tracr-
RNA), a crRNA containing a 20 bp region (protospacer) 
homologous to the target sequence, and the Cas9 nucle-
ase. The association of the tracrRNA and the crRNA with 
Cas9 activates the nuclease, thereby promoting crRNA 
directed cleavage of the target DNA. In an experimental 
context, the functions of the two RNAs can be combined 
into a single hybrid gRNA (guide RNA), which means 
that delivery of a single gRNA and Cas9 protein are suf-
ficient to direct genome editing in any cell type. Site-
specific cleavage by the RNA/Cas9 complex also requires 
that target sequences are abutted by a short sequence 
recognised by Cas9, the protospacer adjacent motif 
(PAM). This additional sequence tag, typically 5′-NGG-
3′, ensures that in bacteria the system recognises invading 
PAM-containing DNA, but not host CRISPR-associated 
protospacer DNA that lacks adjacent PAMs. Since the 
frequency of 5′-NGG-3′ PAM sequence in the AT-rich rat 
genome occurs on average every 16–18 bp, much of the 
rat genome is accessible to CRISPR/Cas-directed gene 
editing, although in some instances this may prove limit-
ing for knock-in strategies which require the cut site to be 
less than 20  bp from the intended insertion site (Flister 
et al. 2015). Furthermore, the short recognition sequence 
of the CRISPR/Cas system may restrict the targeting of 
repetitive sequences and closely related genes containing 
similar sequences.
CRISPR/Cas‑generated knock‑out rats
The simplicity and flexibility of the CRISPR/Cas editing 
system was immediately recognised by groups working 
with the rat, and is now the preferred editing platform for 
the standard NHEJ- and HDR-based techniques. Indeed, 
a major additional advantage of the CRISPR/Cas RNA-
based recognition system is that it can be multiplexed. This 
opens up the possibility of being able to generate multiple 
mutants in a single round of embryo injections, but has 
also facilitated the development of more complex targeting 
strategies.
In 2013, the first reports emerged that described mutant 
rats generated using the CRISPR/Cas system. Li et al. co-
injected gRNAs targeting the gene encoding melanocor-
tin receptors (Mc3r/Mc4r), and confirmed that the pheno-
type of a CRISPR/Cas-generated biallelic Mc4r mutant 
rat was similar to a chemically induced Mc4r mutant (Li 
et  al. 2013a). In a concurrent report, researchers demon-
strated the biological potential of multiplex CRISPR/Cas 
editing by targeting the Tet gene family of DNA hydroxy-
methylases (Li et al. 2013b). Injection of combinations of 
the gRNAs against Tet1, Tet2 and Tet3 genes generated 
rats with compound mutations of all three targets, includ-
ing Tet1/Tet2 double mutant animals. In contrast, bial-
lelic mutations of the Tet3 gene were embryonic lethal, 
demonstrating the essential requirement for Tet3 during 
embryonic development. This experiment demonstrated the 
potential of CRISPR/Cas approach to interrogate a biologi-
cal process such as DNA hydroxymethylation through the 
simultaneous mutation of multiple genes in the rat. A sub-
sequent report also described similar success in applying 
multiplex mutagenesis to a more disparate group of genes, 
ApoE, B2m, Prf1 and Prkdc (Ma et al. 2014b). Co-injection 
with a mixture of four gRNAs, each targeting one gene, 
generated 15 pups in which three contained one mutant 
gene, six contained two mutant genes, five contained three 
mutant genes and one contained mutations in all four genes.
Initially concerns were raised that the more limited 20 bp 
gRNA recognition sequence might mean that the CRISPR/
Cas system would incur higher levels of off-target cleavage, 
when compared with the longer 30–36 bp target sequences 
recognised by ZFN and TALEN dimers. Although sys-
tematic comparisons across platforms are not available, 
the consensus based on reports to date, suggests that the 
CRISPR/Cas system is no worse than other gene editors. In 
fact, the limited recognition sequence and its reliance upon 
accurate hybridisation between gRNA and target DNA 
means that this system can be used to discriminate between 
gene variants and selective targeting of specific alleles. In 
an elegant experiment, Yoshimi et  al. turned this to their 
advantage demonstrating that a single base pair difference 
between the mutant (albino) and wild-type alleles of the 
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coat colour tyrosinase gene was only targeted by the allele-
specific gRNAs (Yoshimi et al. 2014). This was most con-
clusively demonstrated in vivo, in F1 embryos from albino 
(F344) × wt (DA) rat crosses, where the injected gRNAs 
could discriminate between the different alleles. Interest-
ingly, a TALEN designed to target the mutant albino allele 
could not distinguish between the alleles and cut both 
equally well. Taken together these experiments showed the 
sequence specificity of the CRISPR/Cas targeting system 
and highlighted the potential applications of the system in 
selectively correcting disease-associated alleles.
CRISPR/Cas‑generated conditional knock‑out rats
NHEJ-based mutagenesis using CRISPR/Cas in rat 
embryos is clearly highly efficient but constitutive muta-
tions can limit analyses when investigating the functions 
of target genes that are essential for embryonic develop-
ment or general viability. The ability to conditionally ablate 
gene function through the Cre/loxP recombination system 
circumvents this limitation. Using the CRISPR/Cas sys-
tem to stimulate HDR, researchers have generated condi-
tional alleles following microinjection of Cas9 mRNA/
protein and gRNA into zygotes. Ma et  al. used circular 
templates in which the first exons of the DNA methyltrans-
ferase enzymes, Dnmt1, Dnmt3a and Dnmt3b were flanked 
with loxP recombination sites (Ma et  al. 2014c). Impor-
tantly, in this approach, the loxP sites were positioned so 
that they disrupted the gRNA target sites, thus protecting 
the HDR template from cleavage. Interestingly, the use of 
two gRNAs that cleave at either side of the floxed exon, 
promoted HDR in approximately 30% of pups targeted at 
either the Dnmt3a or 3b locus, whereas the efficiency was 
somewhat lower (16%) for the single cut approach used 
for the Dnmt1 gene. Whether the location of the cleavage 
sites or the use of two gRNAs was important in promot-
ing recombination is not clear from this study. Nonetheless, 
this group used the same protocol to generate EGFP and 
CRE-recombinase knock-in rats (Ma et  al. 2014a). Using 
microinjection of circular plasmids as the HDR template 
along with two gRNAs, the efficiency of correct targeting 
ranged from 23 to 54% of pups born. Nestin and Cholecys-
tokinin-CRE knock-in rats were crossed with rats carrying 
floxed Dnmt alleles to produce double transgenic F1 rats 
that had correctly recombined mutant Dnmt alleles in the 
hippocampal region of the brain, thereby demonstrating the 
utility of these new CRE driver transgenic lines.
In a further elaboration of the Cre/loxp system, Wang 
et  al. inserted an inverted splice acceptor GFP reporter 
cassette downstream of Exon 1 in the Lgr5 gene by micro-
injection of Cas9 protein and gRNA mRNA (Wang et  al. 
2015a). Lgr5 is a marker of stem cell compartments in a 
variety of tissues including the intestine, stomach and hair 
follicle (Muñoz et al. 2012) and is a powerful tool in line-
age tracing experiments. The GFP reporter cassette, flanked 
at either side by nested loxP sites (Lox66 and Lox71), was 
inserted by CRISPR/Cas-directed HDR to generate trans-
genic founder animals at a frequency of 66%. Subsequent 
Cre-mediated inversion of the cassette placed the EGFP 
reporter under the control of the Lgr5 gene resulting in 
expression of EGFP within the crypts of the rat intestine.
In a recent simplification of the CRISPR/Cas HDR 
technology, electroporation of long single-stranded DNA 
(lssDNA) as the HDR template, along with two gRNAs 
allows efficient generation of conditionally floxed alleles in 
rat zygotes in the “CLICK” (CRISPR with lssDNA induc-
ing conditional knock-out alleles) method (Miyasaka et al. 
personal communication). The advantage of the lssDNA 
template is that it can be quickly and simply prepared from 
custom-made plasmids using nicking endonucleases. Using 
a lssDNA to the rat Vapb gene (vesicle-associated mem-
brane protein-associated protein B/C), Mashimo and col-
leagues inserted the P56S mutation associated with amyo-
trophic lateral sclerosis in humans (Nishimura et al. 2004) 
into a floxed exon 2 of rat Vapb. Half of the rats born car-
ried at least one floxed allele with the P56S mutation. In a 
further refinement to this methodology, the CLICK method 
can also be applied to zygotes that carry transgenes driving 
tissue-specific Cre recombinase, thereby enabling the one-
step generation of conditional knock-out animals.
Large‑scale rearrangements using single‑stranded 
oligodeoxynucleotide templates
The previous examples of standard HDR approaches used 
plasmid DNA templates. However, a number of reports 
have demonstrated how single-stranded oligodeoxynu-
cleotides (ssODNs) combined with CRISPR/Cas editors 
can serve as highly selective tools for template-directed 
mutagenesis (Wang et  al. 2013; Yang et  al. 2013). To 
explore the applications of ssODN gene editing in the rat, 
Yoshimi and colleagues used ssODNs in three different 
scenarios to manipulate the coat colour genetics of F344 
rats: (1) they used a wild-type ssODN to exchange a single 
base pair in the coat colour gene tyrosinase, thus reverting 
the albino allele back to wild-type sequence and restor-
ing a non-albino pigmentation pattern, (2) they inserted 
an additional 19 bp sequence contained in an ssODN into 
the mutant Agouti-signalling gene Asipa locus to recover 
agouti coat colour and (3) they used two flanking gRNAs to 
delete a 7000 bp ERV retroviral element from the Kit gene, 
using a ssODN containing homology on either side of the 
junction to bridge across the deletion—thus restoring Kit 
gene function and a non-hooded pigmentation pattern. The 
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frequency of correctly edited pups in these experiments 
ranged between 4 and 18% demonstrating the feasibility 
of using ssODNs to create a variety of precise template-
directed mutations in rats (Yoshimi et al. 2014).
The successful use of an ssODN to paste together two 
non-adjacent DNA ends, suggested that a similar approach 
might be effective in joining DNA fragments in trans, 
for example, ligating an exogenous DNA sequence to the 
chromosome. This approach in its most simple format 
requires the cleavage of a genomic target site and a donor 
plasmid with gRNAs in the presence of two ssODNs that 
carry the requisite regions of homology to the genome 
and plasmid sequences (Fig.  2). Using this approach, 
Yoshimi and colleagues inserted plasmid DNA containing 
a GFP expression construct into the ROSA26 locus, and 
placed an entire 200  kb human BAC encoding the anti-
phagocytic signal regulatory protein alpha (SIRPA) gene 
into the rat Sirpa locus (Yoshimi et  al. 2016). In this lat-
ter example, the BAC insertion directed expression of the 
human gene and eliminated expression of the endogenous 
rat gene, effectively humanising the rat at this locus. How-
ever, retention of the rat gene regulatory sequences may in 
some instances be an undesirable complication. To cleanly 
engineer a gene replacement, the endogenous gene can be 
deleted using two gRNAs, whilst the donor plasmid is lin-
earised with a gRNA, and the appropriate ends of DNA are 
pasted together using two bridging ssODNs. Using such 
an approach the entire 58 kb rat Cyp2d locus was replaced 
with the 6.2 kb human CYP2D6 gene (Yoshimi et al. 2016). 
A major advantage of using ssODNs to paste together DNA 
ends is that it eliminates a requirement for lengthy homol-
ogy arms on the donor DNA. However, a minor limitation 
of these current schemes is the co-integration of plasmid 
backbone sequences, along with the donor gene, which may 
not be desirable since bacterial sequences can attract and 
seed unwanted epigenetic modifications and have unpre-
dictable consequences on gene expression. Nonetheless, 
unwanted sequences could be eliminated by gRNA-directed 
deletion in a second round of gene editing, if necessary.
Conclusions and future perspectives
The rat has long been recognised as the preferred experi-
mental animal in many areas of biomedical science because 
of its physiology, behavioural characteristics, size and genet-
ics. Through the recent development of rat ES cell and gene 
editing technologies, researchers are now in a position to 
fully exploit the untapped biological potential of this useful 
laboratory rodent. Using CRISPR/Cas-directed homologous 
recombination, we can now create specific targeted knock-
outs in genes, knock-in transgenes, perform gene replace-
ments and conditionally delete genes at will, opening the way 
to take full advantage of the wealth of genetic and physiologi-
cal information that has been accrued since the first studies 
used rats over a century ago. This will allow us to explore 
the genetics underlying the biomedically related phenotypes 
of existing rat strains, and to directly model the genetic basis 
of many human diseases. Given the rapid pace at which gene 
editing has developed in the last few years, it is likely that 
further increases in the efficiency of the CRISPR/Cas system 
will soon mean that introduction of some types of mutation 
into the germ line is no longer the limiting factor. However, 
gene editing increases the efficiency of gene targeting in rat 
ESCs (Tong et  al. 2012; Yamamoto et  al. 2015) and there-
fore CRISPR/Cas-mediated-targeting in ES cells can usefully 
Fig. 2  CRISPR/Cas9-mediated large-scale genomic deletions and 
replacements. Large-scale genomic deletions or replacements can be 
achieved using pairs of Cas9/gRNAs designed to flank and excise the 
region to be deleted/replaced. a For deletions, a single ssODN con-
taining sequence homology to either side of the cleavage site acts as 
a ‘bridge’ to paste together the non-adjacent ends. b For replacement, 
a donor plasmid containing the replacement sequence is linearised 
using a third Cas9/gRNA. Replacement at the desired locus is facili-
tated by the use of two ssODNs each containing sequence homology 
to either side of the two cleavage sites bridging the non-adjacent ends
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complement in ovo gene editing experiments to enable the 
pre-selection of biologically relevant mutations and the gen-
eration of more complex genetic modifications. ES cells can 
model many features of early embryonic development and 
generate many specific cell types in vitro, thus providing the 
means to interrogate and screen the function of large numbers 
of candidate genes in biologically relevant cell types. Moreo-
ver, the ability to screen many hundreds of clones to identify 
relatively rare events, and then serially repeat these target-
ing procedures in culture prior to embarking on experiments 
in vivo is a significant advantage of using ES cells. For exam-
ple, these features of ES cells have already been exploited in 
the implementation of large-scale programmes to completely 
humanise large sections of up to 6  Mb of chromosomes in 
the mouse (Wallace et al. 2007; Lee et al. 2014; Macdonald 
et al. 2014). The application of similar approaches to rat ES 
cells could be used to humanise significant regions of the rat 
genome, generating unique models that in a second phase of 
genetic engineering could be rapidly modified in transgenic 
rats using standard in ovo gene editing techniques. In this 
way, whilst CRISPR/Cas-mediated gene editing will take 
the lead in the immediate future, longer-term objectives and 
more complex projects may benefit from a blend of ES cell 
and gene editing technologies to deliver the full potential of 
the rat as a pre-eminent experimental animal model in bio-
medical research. Incidentally, combining the use of induced 
pluripotent stem cells together with in ovo gene editing will 
also surely have wider applications in effectively implement-
ing genetic engineering and editing in other commercially 
important species such as livestock.
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